BMS’s and Nektar Therapeutics’s Join Study of Bempegaldesleukin in Combination with Opdivo for Treatment of Melanoma Failed to Meet Expectations
Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) have announced an update following the first analysis of the…